Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A

  1. Antonietta Franco
  2. Xiawei Dang
  3. Emily K Walton
  4. Joshua N Ho
  5. Barbara Zablocka
  6. Cindy Ly
  7. Timothy M Miller
  8. Robert H Baloh
  9. Michael E Shy
  10. Andrew S Yoo
  11. Gerald W Dorn II  Is a corresponding author
  1. Washington University School of Medicine, United States
  2. Mossakowski Medical Research Centre, Poland
  3. Cedars-Sinai Medical Center, United States
  4. Carver College of Medicine, University of Iowa, United States

Abstract

Charcot-Marie-Tooth disease type 2A (CMT2A) is an untreatable childhood peripheral neuropathy caused by mutations of the mitochondrial fusion protein, mitofusin (MFN) 2. Here, pharmacological activation of endogenous normal mitofusins overcame dominant inhibitory effects of CMT2A mutants in reprogrammed human patient motor neurons, reversing hallmark mitochondrial stasis and fragmentation independent of causal MFN2 mutation. In mice expressing human MFN2 T105M, intermittent mitofusin activation with a small molecule, MiM111, normalized CMT2A neuromuscular dysfunction, reversed pre-treatment axon and skeletal myocyte atrophy, and enhanced axon regrowth by increasing mitochondrial transport within peripheral axons and promoting in vivo mitochondrial localization to neuromuscular junctional synapses. MiM111-treated MFN2 T105M mouse neurons exhibited accelerated primary outgrowth and greater post-axotomy regrowth, linked to enhanced mitochondrial motility. MiM111 is the first pre-clinical candidate for CMT2A.

Data availability

All data generated or analyzed during this study are included in the manuscript.

Article and author information

Author details

  1. Antonietta Franco

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5487-1800
  2. Xiawei Dang

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0343-7107
  3. Emily K Walton

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  4. Joshua N Ho

    Department of Developmental Biology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  5. Barbara Zablocka

    Molecular Biology Unit, Mossakowski Medical Research Centre, Warsaw, Poland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2204-5184
  6. Cindy Ly

    Department of Neurology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  7. Timothy M Miller

    Department of Neurology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  8. Robert H Baloh

    Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  9. Michael E Shy

    Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, United States
    Competing interests
    No competing interests declared.
  10. Andrew S Yoo

    Department of Developmental Biology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0304-3247
  11. Gerald W Dorn II

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    For correspondence
    gdorn@wustl.edu
    Competing interests
    Gerald W Dorn II, G.W.D. is an inventor on patent applications PCT/US18/028514 submitted by Washington University and PCT/US19/46356 submitted by Mitochondria Emotion, Inc that cover the use of small molecule mitofusin agonists to treat chronic neurodegenerative diseases, and is a founder of Mitochondria in Motion, Inc., a Saint Louis based biotech R&D company focused on enhancing mitochondrial trafficking and fitness in neurodegenerative diseases..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8995-1624

Funding

NIH (R35HL135736)

  • Gerald W Dorn II

NIH (R41NS113642)

  • Gerald W Dorn II

NIH (R41NS115184)

  • Gerald W Dorn II

Muscular Dystrophy Association (628906)

  • Gerald W Dorn II

McDonnell Center for Cellular and Molecular (Neurobiology Postdoctoral Fellowship)

  • Antonietta Franco

Harrington Discovery Institute (Scholar-Innovator awardee)

  • Gerald W Dorn II

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experimental procedures were approved by Washington University in St. Louis School of Medicine Animal Studies Committee; IACUC protocol number 19-0910, Exp:12/16/2022 (Gerald Dorn, PI).

Copyright

© 2020, Franco et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,191
    views
  • 536
    downloads
  • 42
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

Share this article

https://doi.org/10.7554/eLife.61119

Further reading

    1. Cell Biology
    Yan Song, Linda J Fothergill ... Gene W Yeo
    Research Article

    Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.

    1. Cell Biology
    2. Developmental Biology
    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.